{"id":"https://openalex.org/W4361908446","doi":"https://doi.org/10.1158/1078-0432.22450547.v1","title":"Supplementary Figure 1 from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma","display_name":"Supplementary Figure 1 from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361908446","doi":"https://doi.org/10.1158/1078-0432.22450547.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22450547.v1","doi":"https://doi.org/10.1158/1078-0432.22450547.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450547.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_BRAF_Inhibition_Is_Associated_with_Enhanced_Melanoma_Antigen_Expression_and_a_More_Favorable_Tumor_Microenvironment_in_Patients_with_Metastatic_Melanoma/22450547/1/files/39901625.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_BRAF_Inhibition_Is_Associated_with_Enhanced_Melanoma_Antigen_Expression_and_a_More_Favorable_Tumor_Microenvironment_in_Patients_with_Metastatic_Melanoma/22450547/1/files/39901625.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5047185974","display_name":"Dennie Tompers Frederick","orcid":"https://orcid.org/0000-0003-3355-5267","observed_orcids":["https://orcid.org/0000-0003-3355-5267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dennie T. Frederick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014864191","display_name":"Adriano Piris","orcid":"https://orcid.org/0000-0003-1081-9821","observed_orcids":["https://orcid.org/0000-0003-1081-9821"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adriano Piris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031456140","display_name":"Alexandria P. Cogdill","orcid":"https://orcid.org/0000-0001-8917-9462","observed_orcids":["https://orcid.org/0000-0001-8917-9462"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alexandria P. Cogdill","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071770314","display_name":"Zachary Aaron Cooper","orcid":"https://orcid.org/0000-0003-1059-0940","observed_orcids":["https://orcid.org/0000-0003-1059-0940"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zachary A. Cooper","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080410786","display_name":"Cecilia M. Lezcano","orcid":"https://orcid.org/0000-0001-9436-9623","observed_orcids":["https://orcid.org/0000-0001-9436-9623"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cecilia Lezcano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103094053","display_name":"Cristina R. Ferrone","orcid":"https://orcid.org/0000-0002-9465-7008","observed_orcids":["https://orcid.org/0000-0002-9465-7008"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cristina R. Ferrone","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018624284","display_name":"Devarati Mitra","orcid":"https://orcid.org/0000-0002-2225-164X","observed_orcids":["https://orcid.org/0000-0002-2225-164X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Devarati Mitra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109136106","display_name":"Andrea Boni","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrea Boni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083372211","display_name":"Lindsay P. Newton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lindsay P. Newton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066028652","display_name":"Chengwen Liu","orcid":"https://orcid.org/0000-0002-3930-7793","observed_orcids":["https://orcid.org/0000-0002-3930-7793"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chengwen Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071360122","display_name":"Weiyi Peng","orcid":"https://orcid.org/0000-0002-7785-6240","observed_orcids":["https://orcid.org/0000-0002-7785-6240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Weiyi Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087211162","display_name":"Ryan J. Sullivan","orcid":"https://orcid.org/0000-0001-5344-6645","observed_orcids":["https://orcid.org/0000-0001-5344-6645"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ryan J. Sullivan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049839632","display_name":"Donald P. Lawrence","orcid":"https://orcid.org/0000-0001-5288-9110","observed_orcids":["https://orcid.org/0000-0001-5288-9110"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald P. Lawrence","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044032746","display_name":"Willem W. Overwijk","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Willem W. Overwijk","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052355478","display_name":"Gregory A. Lizee","orcid":"https://orcid.org/0000-0003-4449-7461","observed_orcids":["https://orcid.org/0000-0003-4449-7461"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory Liz\u00e9e","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018856906","display_name":"G\u00eborge F. Murphy","orcid":"https://orcid.org/0000-0001-9362-5146","observed_orcids":["https://orcid.org/0000-0001-9362-5146"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"George F. Murphy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033798832","display_name":"Patrick Hwu","orcid":"https://orcid.org/0000-0002-8293-1313","observed_orcids":["https://orcid.org/0000-0002-8293-1313","https://orcid.org/0000-0003-0554-2856"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Hwu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023174631","display_name":"Keith T. Flaherty","orcid":"https://orcid.org/0000-0002-3402-0478","observed_orcids":["https://orcid.org/0000-0002-3402-0478"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keith T. Flaherty","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078874539","display_name":"David E. Fisher","orcid":"https://orcid.org/0000-0002-5506-0575","observed_orcids":["https://orcid.org/0000-0002-5506-0575"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David E. Fisher","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5035427219","display_name":"Jennifer Ann Wargo","orcid":"https://orcid.org/0000-0003-3438-7576","observed_orcids":["https://orcid.org/0000-0003-3438-7576"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer A. Wargo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-inhibition","display_name":"BRAF inhibition","score":0.8600000143051147},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9570000171661377},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.972000002861023},{"id":"https://openalex.org/keywords/melan-a","display_name":"Melan-A","score":0.8569999933242798},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.9340000152587891},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.7310000061988831}],"concepts":[{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.8702865839004517},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.758392870426178},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6829463839530945},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5184204578399658},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49760702252388},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.43885213136672974},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35235390067100525},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.1756247580051422},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.170293927192688}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.22450547.v1","doi":"https://doi.org/10.1158/1078-0432.22450547.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450547.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_BRAF_Inhibition_Is_Associated_with_Enhanced_Melanoma_Antigen_Expression_and_a_More_Favorable_Tumor_Microenvironment_in_Patients_with_Metastatic_Melanoma/22450547/1/files/39901625.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22450547","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_BRAF_Inhibition_Is_Associated_with_Enhanced_Melanoma_Antigen_Expression_and_a_More_Favorable_Tumor_Microenvironment_in_Patients_with_Metastatic_Melanoma/22450547","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22450547.v1","doi":"https://doi.org/10.1158/1078-0432.22450547.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22450547.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_BRAF_Inhibition_Is_Associated_with_Enhanced_Melanoma_Antigen_Expression_and_a_More_Favorable_Tumor_Microenvironment_in_Patients_with_Metastatic_Melanoma/22450547/1/files/39901625.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361908446.pdf","grobid_xml":"https://content.openalex.org/works/W4361908446.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1991879524","https://openalex.org/W2171435634","https://openalex.org/W2066581032","https://openalex.org/W4292582583","https://openalex.org/W2079364398","https://openalex.org/W2079772486","https://openalex.org/W4248678482","https://openalex.org/W95056088","https://openalex.org/W2011769377","https://openalex.org/W2337657580"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"112K,":[3],"Inhibition":[4],"of":[5,9,13],"BRAFV600E":[6],"increases":[7],"expression":[8],"MART-1":[10],"in":[11],"tumors":[12],"patients":[14],"with":[15],"metastatic":[16],"melanoma.":[17]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2025-10-10T00:00:00"}